Radiopharmaceutical company Lantheus Holdings has completed the acquisition of Evergreen Theragnostics, a clinical-stage radiopharma company with an integrated CDMO business.
This acquisition will add to Lantheus' capabilities in the radiopharmaceutical space, allowing the company access to Evergreen's radioligand therapy manufacturing infrastructure.
The company's CDMO sector can also offer clients its radiochemistry development and manufacturing capabilities, as well as alpha therapy and isotope production services in its dedicated cleanroom facility.
Lantheus will also acquire Evergreen's OCTEVY, a PET diagnostic imaging agent that is currently at the registrational stage.
OCTEVY is designed to target neuroendocrine tumours, which complements PNT2003, Lantheus' current therapeutic candidate.
“As we continue in our efforts to expand our radiopharmaceutical leadership, we've excited to welcome Evergreen's talented team to Lantheus," comments the company's CEO, Brian Markinson.
“By acquiring Evergreen Theragnostics, we are enhancing Lantheus’ capabilities across the entire radiopharmaceutical value chain, from development to manufacturing to commercialisation. With Evergreen’s scalable manufacturing infrastructure and expertise as well as its promising pipeline of oncology-focused assets, including OCTEVY, we are better positioned than ever to meet the complex demands of the market."
"We look forward to integrating Evergreen’s capabilities to drive innovation and deliver better outcomes for patients worldwide,” he concluded.